SecBot SecBot
PRESS-RELEASE ·Filed Apr 21, 2026

CRVS

Corvus Pharmaceuticals, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

Monitor the May 14 investor meeting for new biomarker and immunologic data on soquelitinib, which could influence investor sentiment ahead of the Phase 3 readout in PTCL. Absence of a Q1 earnings call suggests limited near-term financial updates.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$17.14
T+0 close · Apr 21, 2026 · via day close
Latest settled
−16.74%
T+60 · $14.27
Vs SPY
−23.64%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 21 $17.14entry
  2. T+1 · 7mo ago +4.14%α +3.12% · $17.85
  3. T+5 · 7mo ago −8.87%α −9.95% · $15.62
  4. T+20 · 6mo ago −28.76%α −33.68% · $12.21
  5. T+60 · 4mo ago −16.74%α −23.64% · $14.27
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Corvus Pharmaceuticals will host an investor meeting on May 14, 2026, to highlight new Phase 1 clinical data for soquelitinib in atopic dermatitis, including late-breaking data on drug-free remissions, presented at the Society for Investigative Dermatology meeting. The company will report Q1 2026 financial results on May 7 but will not hold a conference call.

Key Facts

  • Investor and analyst meeting scheduled for May 14, 2026, to discuss soquelitinib Phase 1 data from the SID Annual Meeting.
  • Two oral presentations at SID include a late-breaking session on drug-free remissions with soquelitinib.
  • Phase 1 trial data is from a randomized, blinded, placebo-controlled study in moderate-to-severe atopic dermatitis.
  • Company to release Q1 2026 financial results on May 7, 2026, without a conference call or webcast.
  • Soquelitinib is an oral, selective ITK inhibitor currently in Phase 3 for relapsed/refractory PTCL and Phase 2 for atopic dermatitis.

Financial Impact

No financial data disclosed in this release; financial results expected May 7.

revenueepscashFlow

Risk Factors

  • Clinical data may not translate into meaningful efficacy in later-stage trials.
  • No conference call for Q1 results may limit transparency and investor engagement.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3277804

Track record

15 reports on CRVS

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +2.61% at T+1 after the Mar 12, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 13, 20263d ago Insider Buy Neutral 3/10 Entry $11.20 Now $10.60 −5.36% settles Feb 12
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $11.37 Now $10.60 −6.77% settles Feb 8
  3. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $10.54 Now $10.60 +0.57% settles Feb 4
  4. Nov 5, 202611d ago Press Release Neutral 4/10 No price data
  5. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $10.57 Now $10.60 +0.28% settles Feb 2
  6. Sep 30, 20266w ago Press Release Neutral 3/10 Entry $10.93 Now $10.60 −3.02% settles Dec 28
  7. Aug 21, 202612w ago Institutional Cluster Bullish 6/10 Entry $14.46 to $10.60 Now $10.60 −26.69% ▼ −26.69% −23.33% vs SPY
  8. Jul 22, 202616w ago 8-K Neutral 2/10 Entry $13.68 to $9.85 Now $10.60 −22.51% ▼ −28.00% −32.55% vs SPY
  9. Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $11.60 to $14.39 Now $10.60 −8.62% ▲ +24.05% +19.66% vs SPY
  10. May 14, 202626w ago 8-K Bullish 7/10 Entry $13.66 to $13.74 Now $10.60 −22.37% ▲ +0.62% −2.97% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 21, 2026